EW Edwards Lifesciences Corp
- Stocks
- Healthcare
- NYSE: EW
Price (delayed)
$79.5
Market cap
$46.63B
P/E Ratio
11.31
Dividend/share
N/A
EPS
$7.03
Enterprise value
$44.19B
Edwards Lifesciences is an American medical technology company headquartered in Irvine, California, specializing in artificial heart valves and hemodynamic monitoring. It developed the SAPIEN transcatheter aortic heart valve made of
Highlights
The net income has soared by 196% YoY
The price to earnings (P/E) is 71% lower than the 5-year quarterly average of 39.0 and 33% lower than the last 4 quarters average of 17.1
Key stats
What are the main financial stats of EW
Market
Valuations
Earnings
Shares outstanding
586.6M
Market cap
$46.63B
Enterprise value
$44.19B
Price to earnings (P/E)
11.31
Price to book (P/B)
4.61
Price to sales (P/S)
8.42
EV/EBIT
10.1
EV/EBITDA
9.7
EV/Sales
7.98
Revenue
$5.54B
Gross profit
$4.4B
Operating income
$1.43B
Net income
$4.18B
EBIT
$4.38B
EBITDA
$4.56B
Free cash flow
$633.1M
Per share
Balance sheet
Liquidity
EPS
$7.03
EPS diluted
$7.03
Free cash flow per share
$1.08
Book value per share
$17.23
Revenue per share
$9.44
TBVPS
$17.16
Total assets
$13.02B
Total liabilities
$2.83B
Debt
$699.4M
Equity
$10.13B
Working capital
$4.82B
Debt to equity
0.07
Current ratio
4.45
Quick ratio
3.33
Net debt/EBITDA
-0.54
Margins
Efficiency
Dividend
EBITDA margin
82.3%
Gross margin
79.4%
Net margin
75.5%
Operating margin
25.8%
Return on assets
34%
Return on equity
45.1%
Return on invested capital
71.9%
Return on capital employed
37.6%
Return on sales
79%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
EW stock price
How has the Edwards Lifesciences stock price performed over time
Intraday
-0.74%
1 week
-1.21%
1 month
3.53%
1 year
30.97%
YTD
7.39%
QTD
1.65%
Financial performance
How have Edwards Lifesciences's revenue and profit performed over time
Revenue
$5.54B
Gross profit
$4.4B
Operating income
$1.43B
Net income
$4.18B
Gross margin
79.4%
Net margin
75.5%
The net income has soared by 196% YoY
The net margin has soared by 175% YoY
The operating income has grown by 10% YoY and by 3.5% from the previous quarter
EW's revenue is up by 8% year-on-year
Price vs fundamentals
How does EW's price correlate with its fundamentals
Growth
What is Edwards Lifesciences's growth rate over time
Valuation
What is Edwards Lifesciences stock price valuation
P/E
11.31
P/B
4.61
P/S
8.42
EV/EBIT
10.1
EV/EBITDA
9.7
EV/Sales
7.98
The price to earnings (P/E) is 71% lower than the 5-year quarterly average of 39.0 and 33% lower than the last 4 quarters average of 17.1
The stock's price to book (P/B) is 49% less than its 5-year quarterly average of 9.1 and 9% less than its last 4 quarters average of 5.1
The equity has grown by 42% year-on-year
The P/S is 24% below the 5-year quarterly average of 11.1
EW's revenue is up by 8% year-on-year
Efficiency
How efficient is Edwards Lifesciences business performance
The company's return on invested capital has surged by 172% YoY
The company's return on sales has surged by 156% YoY
EW's return on assets has surged by 125% year-on-year but it is down by 7% since the previous quarter
Edwards Lifesciences's return on equity has surged by 114% YoY but it has decreased by 8% QoQ
Dividends
What is EW's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for EW.
Financial health
How did Edwards Lifesciences financials performed over time
EW's quick ratio is up by 44% year-on-year and by 7% since the previous quarter
The total assets is up by 34% year-on-year
The debt is 93% less than the equity
The equity has grown by 42% year-on-year
The company's debt to equity fell by 30% YoY
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.